News
Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID study for AstraZeneca's ticagrelor (Brilinta) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
March 25, 2014
Feature
UC Davis clinicians and physicists have recommended new strategies to make computed tomography (CT) safer, including adoption of a new metric for dose measurement, ways to manage exposure protocols that differ by CT brand and specific approaches to reduce exposure during needle biopsies.
March 25, 2014Technology
Digisonics will showcase its upcoming DigiView Release 3.8.4. for its Cardiovascular Information System (CVIS) at this year’s American College of Cardiology (ACC) annual scientific session in Washington, D.C., March 28-31.
March 25, 2014Sponsored Content
Feature | Nuclear Imaging
Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...
November 12, 2025
Feature
Computed tomography (CT) imaging utilization has grown markedly across many clinical disciplines during the past decade, raising concerns about radiation overexposure.
March 24, 2014Technology
Health Level announced the availability of Foundations Cardiology, a packaged solution that increases the speed and agility for cardiology centers by blending data from multiple applications and extending the role of the data warehouse to include real-time data analytics.
March 24, 2014News
BioTelemetry Inc. entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems Corp. (BMS) for aggregate consideration of $8.65 million at closing.
March 24, 2014Sponsored Content
Feature
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
June 17, 2025Feature
Sorin Group has purchased Oscor Inc. lead business, including a lead manufacturing facility in the Dominican Republic for a value of approximately $20 million.
March 24, 2014
Technology
New Vinyl Blood Pressure Cuffs from SunTech Medical deliver accurate blood pressure (BP) readings while providing an economical alternative to traditional durable blood pressure cuffs. Designed for short-term use, these easily cleaned cuffs work with automated BP monitors in clinical areas such as hospital emergency rooms and EMS transport where disinfection is critical.
March 24, 2014
Feature
Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation who cannot tolerate blood-thinning medication.
March 24, 2014Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
Technology
ScImage Inc. has partnered with Cedaron Medical Inc. to deliver CardiacCare with ScImage’s enterprise picture archive and communications system (PACS), PICOM365.
March 24, 2014
News
Boston Scientific Corp. received CE marking and launched in Europe the Ingevity family of magnetic resonance imaging (MRI) compatible pacing leads. The Ingevity family is a set of leads that can be placed using a 6 French introducer, including passive and active fixation models. Ingevity MRI pacing leads are part of the ImageReady MR-conditional pacemaker system, which includes Vitalio MRI, Formio MRI, Advantio MRI and Ingenio MRI pulse generators. When used with the Latitude NXT patient management system, these devices wirelessly monitor patients for conditions such as atrial arrhythmias.
March 21, 2014
Technology
AccessClosure plans to launch the Mynx Ace Vascular Closure Device at the 2014 American College of Cardiology meeting, March 29-31. It is an upgrade of the company’s Mynx mechanical vascular closure product. It is designed to provide patient comfort and uses an easy-to-use deployment system to seal femoral artery access sites. The device helps reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures.
March 21, 2014Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
Case Study
Today, PinnacleHealth is home to one of the foremost transcatheter aortic valve replacement (TAVR) programs in the world. But in the program’s infancy, PinnacleHealth needed to develop relationships between clinicians and facilitate their collaboration using the right diagnostic imaging technology to ensure success. Using a multidisciplinary, collaborative commitment from clinicians and a state-of-the-art hybrid OR lab anchored by Toshiba’s Infinix-i cardiovascular imaging system, PinnacleHealth is improving outcomes for some of its sickest patients. As one of the finest TAVR programs available today, it is also achieving fewer readmissions and lowering costs.
March 19, 2014Feature
Surgeons in France have successfully replaced the aortic valve in two patients without opening the chest during surgery. The procedure, using totally endoscopic aortic valve replacement (TEAVR), shows potential for improving quality of life of heart patients by offering significantly reduced chest trauma. It is described in The Journal of Thoracic and Cardiovascular Surgery.
March 19, 2014
Feature | Dave Fornell
Percutaneous ventricular assist (pVAD) devices offer more hemodynamic support than the 40-year-old gold standard of intra-aortic balloon pumps (IABPs), but their cost and complexity has limited their use to all but the sickest patients. However, the quest for improving patient outcomes and new applications of pVADs for right ventricular support and heart failure indications continues to expand interest in these devices. Several of these new technologies were highlighted in sessions during the 2013 Transcatheter Cardiovascular Therapeutics (TCT) last fall.
March 18, 2014